200 related articles for article (PubMed ID: 12787420)
1. Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
Markowitz GS; Fine PL; Stack JI; Kunis CL; Radhakrishnan J; Palecki W; Park J; Nasr SH; Hoh S; Siegel DS; D'Agati VD
Kidney Int; 2003 Jul; 64(1):281-9. PubMed ID: 12787420
[TBL] [Abstract][Full Text] [Related]
2. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
Banerjee D; Asif A; Striker L; Preston RA; Bourgoignie JJ; Roth D
Am J Kidney Dis; 2003 May; 41(5):E18. PubMed ID: 12778436
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Herlitz LC; Mohan S; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
Kidney Int; 2010 Dec; 78(11):1171-7. PubMed ID: 20811330
[TBL] [Abstract][Full Text] [Related]
4. Early onset acute tubular necrosis following single infusion of zoledronate.
Yachoui R
Clin Cases Miner Bone Metab; 2016; 13(2):154-156. PubMed ID: 27920815
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate nephrotoxicity.
Perazella MA; Markowitz GS
Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
[TBL] [Abstract][Full Text] [Related]
6. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Merigo E; Manfredi M; Meleti M; Corradi D; Vescovi P
J Oral Pathol Med; 2005 Nov; 34(10):613-7. PubMed ID: 16202082
[TBL] [Abstract][Full Text] [Related]
7. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
8. The morphology of "acute tubular necrosis" in man: analysis of 57 renal biopsies and a comparison with the glycerol model.
Solez K; Morel-Maroger L; Sraer JD
Medicine (Baltimore); 1979 Sep; 58(5):362-76. PubMed ID: 481195
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate-induced nephrotoxic tubular necrosis--a case report.
Smetana S; Michlin A; Rosenman E; Biro A; Boaz M; Katzir Z
Clin Nephrol; 2004 Jan; 61(1):63-7. PubMed ID: 14964460
[TBL] [Abstract][Full Text] [Related]
10. [Zoledronate-associated end stage renal failure and hypocalcaemia].
Ramazzina C; Zysset Aschmann Y; Kummer O; Rätz Bravo AE; Bodmer M
Praxis (Bern 1994); 2007 Apr; 96(17):673-6; quiz 677-8. PubMed ID: 17491196
[TBL] [Abstract][Full Text] [Related]
11. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
13. A role for extrarenal cells in the regeneration following acute renal failure.
Gupta S; Verfaillie C; Chmielewski D; Kim Y; Rosenberg ME
Kidney Int; 2002 Oct; 62(4):1285-90. PubMed ID: 12234298
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Cha YJ; Lee YJ
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
Bergner R; Siegrist B; Gretz N; Pohlmeyer-Esch G; Kränzlin B
Pharmacol Res; 2015 Sep; 99():16-22. PubMed ID: 25976681
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
17. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients.
Schiffl H
Nephrol Dial Transplant; 2006 May; 21(5):1248-52. PubMed ID: 16449291
[TBL] [Abstract][Full Text] [Related]
18. Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate.
Neyra JA; Vaidya OU; Hendricks A; Sambandam KK
Nephron Extra; 2014 Sep; 4(3):168-74. PubMed ID: 25473406
[TBL] [Abstract][Full Text] [Related]
19. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.
Fabrizi F; Aghemo A; Fogazzi GB; Moroni G; Passerini P; D'Ambrosio R; Messa P
Kidney Blood Press Res; 2013; 38(1):52-60. PubMed ID: 24556714
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
